Arndt Vogel, MD

Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study

Background Pembrolizumab demonstrated efficacy and a manageable adverse event profile in sorafenib-treated patients with aHCC in KEYNOTE-224, leading to accelerated approval in the Unite...

Arndt Vogel , MD;

06/27/2022

Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study

BackgroundAssociated with a poor prognosis, there is an increased medical need for BRAFV600E-mutant metastatic colorectal cancer (mCRC) patients for improved therapeutic approaches. Upon ...

Arndt Vogel , MD;

06/25/2023

Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy

BackgroundAtezolizumab plus bevacizumab (A+B) is the recommended first line for unresectable HCC (uHCC) in patients with well-preserved liver function. Emerging evidence supports the safe...

Arndt Vogel , MD;

06/25/2023

Brightline-2: A phase IIa/IIb, open-label trial of the MDM2–p53 antagonist BI 907828 in patients with advanced MDM2-amplified, TP53 wild-type biliary tract cancer, pancreatic ductal adenocarcinoma, or other selected solid tumours

BackgroundFurther therapeutic options are urgently required for patients with biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma and bladder cancer, ...

Arndt Vogel , MD;

06/25/2023

An improved personalized medicine network: The PLATON from GI and beyond

BackgroundPersonalized medicine aims to treat patients individually according to their biological and molecular features by directly targeting tumor-specific markers. Gastrointestinal can...

Arndt Vogel , MD;

06/25/2023

Recruitment of gastrointestinal cancer patients via PLATON Network: An interactive precision oncology platform

BackgroundThe success of targeted therapies can be evaluated via clinical trials with a wide range of patient cohorts. On the other hand, patient enrolment is one of the main limiting fac...

Arndt Vogel , MD;

06/25/2023

An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer

Background Patritumab deruxtecan (HER3-DXd) is a novel, investigational antibody-drug conjugate comprising an anti-HER3 monoclonal antibody, a tetrapeptide-based linker,...

Arndt Vogel , MD;

06/28/2021

Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial

Isocitrate dehydrogenase 1 mutation ( IDH1m ) is detected in approximately 13% of patients with cholangiocarcinoma (CCA). In the global, phase 3 ClarIDHy study evaluating ivosidenib (IVO)...

Arndt Vogel , MD;

06/25/2023

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC

Background For the therapy of previously treated BRAF V600E-mutant metastatic colorectal cancer, the combination of encorafenib with cetuximab represents a new standard ...

Arndt Vogel , MD;

06/28/2021

Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study

Fibroblast growth factor receptor 2 ( FGFR2 ) fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma (iCCA). Futibatinib is a highly selective, cova...

A. Hollebecque ;

Arndt Vogel , MD;

06/25/2023